Gilead licences Xilio’s IL-12 candidate XTX301 in deal worth up to $647.5m
XTX301, which is a tumour-activated IL-12 designed to accelerate anti-tumour immunity, is currently being evaluated for its safety…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
29 Mar 24
XTX301, which is a tumour-activated IL-12 designed to accelerate anti-tumour immunity, is currently being evaluated for its safety…
28 Mar 24
The approval is supported by the safety and efficacy data from the INNO2VATE programme and post-marketing safety data…
27 Mar 24
The FDA approval, following the US FDA Breakthrough Therapy Designation, is based on the results from the Phase…
26 Mar 24
Cardior is engaged in the discovery and development of therapies that prevent, repair and reverse diseases of the…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
26 Mar 24
According to the terms of the agreement, Ferrer will gain the exclusive rights to co-develop and market VRG50635…
26 Mar 24
AUD 17 Million Grant over 5 Years Will Fund Next-Generation TB Cures
26 Mar 24
Hub will focus on supporting global use of new treatments that effectively treated drug-resistant TB in 98% of…
25 Mar 24
The FDA approval of Opsynvi, a combination of two proven treatments with established efficacy and safety profiles into…
25 Mar 24
The approval was based on the findings from the confirmatory Phase 3 MIRASOL trial in which Elahere treatment…
25 Mar 24
The analyses revealed that Rexulti was linked to reductions in both overall neuropsychiatric symptoms and agitation symptoms when…